What You Should Know:
– PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors including Catalio Capital Management, aMoon, Invus and Bruker.
– The funding brings PrognomiQ’s total funding to more than $135M and will accelerate the development of PrognomiQ’s early detection test for lung cancer.
Enhancing Lung Cancer Detection with Multi-Omics
Lung cancer is a leading cause of cancer-related deaths worldwide. Early detection is crucial for improving survival rates, but current screening methods have limitations. PrognomiQ’s multi-omics test addresses this unmet need by providing a more accurate and accessible screening option.PrognomiQ is developing a groundbreaking early-detection test for lung cancer that leverages a multi-omics approach. This approach combines proteomics, genomics, metabolomics, and other data sources to identify potential biomarkers. This innovative approach can potentially transform lung cancer detection and improve patient outcomes.
Promising Research and Development
PrognomiQ has demonstrated promising results in its research:
- Large-Scale Multi-Omics Study: A recent study published in medRxiv analyzed data from over 2,500 subjects, demonstrating 89% sensitivity and specificity in detecting lung cancer, including 80% sensitivity for stage 1 lung cancer.
- CLIA License: The company has been granted a Clinical Laboratory Improvement Amendment (CLIA) license to support the development of its lab-developed test (LDT).
- Prospective Study: PrognomiQ is currently enrolling participants in a 15,000-subject study to support the registration of its in vitro diagnostics (IVD) test.
Expanding Capabilities and Expertise
This new funding will enable PrognomiQ to:
- Advance LDT Development: Accelerate the development and commercialization of its LDT for early lung cancer detection.
- Pursue IVD Registration: Support the ongoing clinical trial and regulatory process for its IVD test.
- Enhance Multi-Omics Platform: Further develop its proprietary multi-omics platform and expand its applications to other complex diseases.
“We’re grateful for the support from our syndicate of investors and board members, who acknowledge the exceptional value of our platform, and the opportunity to advance the development of our transformative, early detection lung cancer products,” said Philip Ma, President and CEO of PrognomiQ. “We are honored and thrilled to have the support of our investors and partners, and to welcome Isaac as an Independent Director. We have an exciting path ahead of as we develop products that have the potential to dramatically improve patient outcomes for lung cancer, the leading cause of cancer-related deaths worldwide, through early detection.”
